Sa1973 Loss of Anti-TNF Drugs Into Feces and Its Impact on Anti- TNF Serum Levels and Clinical Response in Crohn's Disease (CD) Patients

Review article: dose optimisation of infliximab for acute severe ulcerative colitis

“…Brandse et al demonstrated that relatively high concentrations of infliximab can be detected in the faeces of IBD patients, especially in those with severe disease . A similar phenomenon has been observed in patients with Crohn's disease (CD); in a series of 13 patients, faecal concentrations of infliximab and adalimumab were highest in patients with severely active disease and inversely correlated with serum infliximab concentrations . Faecal loss of infliximab presents early, with the highest faecal concentrations seen in the first days following initiation of therapy .…”

“…28 A similar phenomenon has been observed in patients with Crohn's disease (CD); in a series of 13 patients, faecal concentrations of infliximab and adalimumab were highest in patients with severely active disease and inversely correlated with serum infliximab concentrations. 29 Faecal loss of infliximab presents early, with the highest faecal concentrations seen in the first days following initiation of therapy. 28. Anti-drug antibodies: The presence of high serum concentrations of TNF antagonists during induction therapy may protect against formation of anti-drug antibodies.…”